Company News - VC and PE investment business - Medical and health professional investment - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2026 - 04 - 24

EFUNG Capital Secures Multiple Annual Honors at the ChinaVenture Awards

Today, at the highly anticipated "ChinaVenture 20th Annual Investment Summit · Annual Conference," the prestigious ChinaVenture Awards list was officially unveiled. Leveraging its deep expertise in the healthcare industry, EFUNG Capital swept multiple significant institutional and individual awards.EFUNG Capital was honored with: ChinaVenture 2025 Top 50 Best RMB-denominated Venture Capital Firms, ChinaVenture 2025 Top 20 Medical Device Investment Institutions in the Healthcare Sector, and ChinaVenture 2025 Top 100 Best Venture Capital Firms.At the same time, Mr. Zhu Pai, CEO of...

浏览次数：4

查看详情>>

发布时间: 2026 - 04 - 02

When AI Starts "Guiding" Doctors: A New Assistant or a New Rival for Medical Professionals

Editor's NoteLast month, a doctor friend shared his confusion with me.A patient had just sat down when he thrust his phone in front of the doctor. The screen was densely packed with AI-generated "treatment recommendations"—from medication plans to lifestyle restrictions, covering every detail. With a hint of scrutiny, the patient asked: "Doctor, the AI says this medication has serious side effects. Your prescription is different. Could you double-check?"My friend was stunned. He had encountered patients who came with Baidu search results to "argue their case,"...

浏览次数：5

查看详情>>

发布时间: 2026 - 03 - 24

Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration

In March, Suzhou is gradually embracing the vitality of spring, much like China's biomedical industry, which is gathering momentum amidst transformation. On March 13, during the 11th BioChina Summit (BIOCHINA 2026), Mr. Zhu Pai, CEO of Efung Capital, was invited to attend the core session—the Global Investment Forum—where he engaged in in-depth discussions with industry peers on the theme "LP-GP Ecosystem Synergy: Coordinating Policy, Capital, and Innovation."Efung Capital CEO Zhu Pai Attends BIOCHINA 2026: Discussing the New Ecosystem of LP-GP Collaboration, Standing as "Ba...

浏览次数：14

查看详情>>

发布时间: 2026 - 04 - 28

Huahaizhongtian's Utidelone Receives Another FDA Orphan Drug Designation | Feng Investment News

On September 25, Beijing Huahaizhongtian Biopharmaceutical Co., Ltd. (hereinafter referred to as "Huahaizhongtian," stock code: 2563.HK) announced that its core product, Utidelone, has been granted another Orphan Drug Designation by the U.S. Food and Drug Administration (FDA), this time for the treatment of pancreatic cancer. This marks the third Orphan Drug Designation granted to Utidelone by the FDA, following those for breast cancer brain metastases and gastric cancer.Pancreatic cancer is a highly malignant tumor, often referred to as the "king of cancers" due ...

浏览次数：3

查看详情>>